**Abbreviations**

MAPK—mitogen-activated protein kinase; OS—overall survival; ICIs—immune-checkpoint inhibitors; PD-1—anti-programmed death; CTLA-4—anti-cytotoxic T lymphocyte antigen; LDH serum lactate dehydrogenase; S100—S-100 protein; MIA—melanoma inhibitory activity; PTMs post-translational modifications; EZH2—enhancer of zeste 2 polycomb repressive complex 2 subunit; SWI/SNF—switch/sucrose non-fermentable chromatin remodeling complex; pCR—pathological complete response; CDKN2A—cyclin-dependent kinase inhibitor 2; CDK4—cyclin dependent kinase 4; RASSF1A—ras association domain family member; RAR-β2—retinoic acid receptor-beta; WIF-1— WNT inhibitory factor 1; Socs1—suppressor of cytokine signaling 1; TFPI2—tissue factor pathway inhibitor 2; KRTCAP3—keratinocyte associated protein 3; STAT3—signal transducer and activator of transcription 3; NF-κB—nuclear factor kappa B; AGAP2—Arf-GAP with GTPase, ANK repeat and PH domain-containing protein 2; ZNF490—zinc finger protein 490; TTC22—tetratricopeptide repeat protein 22; COL1A2—collagen type I alpha 2 chain; GPX3—glutathione peroxidase 3; CLDN11 claudin 11; CDH11—cadherin 11; PPP1R3C—protein phosphatase 1 regulatory subunit 3C; NPM2 nucleophosmin/nucleoplasmin 2; CCND1—cyclin D1; CCNE1—cyclin E1; E2F3—E2F transcription factor 3; JARID1B—jumonji AT-rich interactive domain 1B; TFPI2—tissue factor pathway inhibitor 2; IDH1/2—isocitrate dehydrogenase <sup>1</sup> 2 ; KDM1A—lysine demethylase 1A; APOBEC2 apolipoprotein B mRNA editing enzyme catalytic subunit 2; SETD4—SET domain containing 4; KDM5B—lysine demethylase 5B; POU3F2—POU class 3 homeobox 2; SOX9—SRY-box transcription factor 9; PDGFRA—Platelet derived growth factor receptor alpha; MITF—melanocyte inducing transcription factor; ZEB2—zinc finger E-box binding homeobox 2; TFAP2A—transcription factor AP-2 alpha; EHMT1—euchromatic histone lysine methyltransferase 1; RTKs—receptor tyrosine kinases; LEF1—lymphoid enhancer binding factor 1; TAP1—transporter associated with antigen processing 1; CD8—cluster of differentiation 8; DUSP4—dual specificity phosphatase 4; CCL3—chemokine (C-C motif) ligand 3; CXCL1—C-X-C motif chemokine ligand 1; TNFα—tumor necrosis factor alpha; p21CIP/WAF1—cyclin-dependent kinase inhibitor 1A.
